COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #68 of 257
6/22 Late treatment study
Fontana et al., Clinical Kidney Journal, 13:3, 334–339, doi:10.1093/ckj/sfaa084 (Peer Reviewed)
SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience
Source   PDF   Share   Tweet
Very small observational study of 15 dialysis patients showing HCQ mortality RR 0.50, p = 0.53.

Fontana et al., 6/22/2020, retrospective, Italy, Europe, peer-reviewed, 8 authors.
risk of death, 50.0% lower, RR 0.50, p = 0.53, treatment 4 of 12 (33.3%), control 2 of 3 (66.7%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 257 studies    Meta analysis
Please send us corrections, updates, or comments.